{
    "nctId": "NCT04750473",
    "briefTitle": "Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer",
    "officialTitle": "Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging",
    "overallStatus": "COMPLETED",
    "conditions": "Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 22,
    "primaryOutcomeMeasure": "Verified detection rate for metastasis",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Treatment naive biopsy proven ILC patients with ILC\n* Either: a) clinical or imaging suspicion of metastatic disease; or b) proven metastatic disease but in whom there is suspicion of an even greater tumor burden that could change therapy approach\n* Ability and willingness to undergo biopsy if needed per standard of care for possible metastasis which could change therapy approach\n\nExclusion Criteria:\n\n* Pregnancy. Qualitative or quantitative serum or urine pregnancy test will be done in women of childbearing potential within 24 hours before PET\n\n  * A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (if age \\> 55 years); if the female subject is \\< 55 years and she has been naturally postmenopausal for \\> 1 year her reproductive status has to be verified by additional lab tests (\\< 20 estradiol OR estradiol \\< 40 with follicle-stimulating hormone \\[FSH\\] \\> 40 in women not on estrogen replacement therapy)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}